Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer; Bone Metastases in Subjects With Advanced Breast Cancer Intervention: Drug: denosumab Sponsor: Amgen Enrolling by invitation - verified August 2011